Brucke Financial Inc. Sells 19 Shares of Eli Lilly and Company $LLY

Brucke Financial Inc. lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,087 shares of the company’s stock after selling 19 shares during the period. Brucke Financial Inc.’s holdings in Eli Lilly and Company were worth $848,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the stock. PDS Planning Inc grew its position in Eli Lilly and Company by 9.8% in the 2nd quarter. PDS Planning Inc now owns 7,382 shares of the company’s stock worth $5,754,000 after purchasing an additional 660 shares during the period. Gunderson Capital Management Inc. grew its position in Eli Lilly and Company by 960.0% in the 2nd quarter. Gunderson Capital Management Inc. now owns 2,703 shares of the company’s stock worth $2,107,000 after purchasing an additional 2,448 shares during the period. Blue Trust Inc. grew its position in Eli Lilly and Company by 76.6% in the 2nd quarter. Blue Trust Inc. now owns 90,111 shares of the company’s stock worth $70,244,000 after purchasing an additional 39,094 shares during the period. Robertson Stephens Wealth Management LLC grew its position in Eli Lilly and Company by 21.4% in the 2nd quarter. Robertson Stephens Wealth Management LLC now owns 7,253 shares of the company’s stock worth $5,654,000 after purchasing an additional 1,278 shares during the period. Finally, Costello Asset Management INC grew its position in Eli Lilly and Company by 14.7% in the 2nd quarter. Costello Asset Management INC now owns 9,035 shares of the company’s stock worth $7,043,000 after purchasing an additional 1,156 shares during the period. Institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of research analyst reports. Cantor Fitzgerald set a $925.00 target price on shares of Eli Lilly and Company and gave the stock an “overweight” rating in a research report on Thursday. Weiss Ratings reiterated a “hold (c+)” rating on shares of Eli Lilly and Company in a research note on Wednesday. Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. HSBC lifted their price target on shares of Eli Lilly and Company from $700.00 to $800.00 in a research note on Wednesday, October 1st. Finally, JPMorgan Chase & Co. dropped their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a research note on Tuesday, September 16th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $948.56.

Insiders Place Their Bets

In related news, Director J Erik Fyrwald purchased 1,565 shares of the firm’s stock in a transaction on Tuesday, August 12th. The shares were acquired at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the purchase, the director directly owned 74,578 shares in the company, valued at $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Jamere Jackson purchased 200 shares of the firm’s stock in a transaction on Friday, August 8th. The stock was bought at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the purchase, the director owned 9,402 shares in the company, valued at approximately $6,013,143.12. This represents a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Stock Down 2.6%

LLY opened at $833.08 on Friday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $937.00. The firm’s fifty day moving average is $742.42 and its 200 day moving average is $766.36. The stock has a market cap of $788.47 billion, a price-to-earnings ratio of 54.45, a price-to-earnings-growth ratio of 1.19 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter in the previous year, the company earned $3.92 EPS. Eli Lilly and Company’s revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.